Chapter 032

Drugs Acting on the Respiratory System

Karen S. Gregson, Bruno Kreiner, and Jeffrey D. Bennett

CITED REFERENCES

  1. Adcock IM, Ito K, Barnes PJ: Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2:445-455, 2005. PUBMED Abstract
  2. Anderson GP: Current issues with β2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. Clin Rev Allergy Immunol 31:119-130, 2006. PUBMED Abstract
  3. Anderson GP, Lindén A, Rabe KF: Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7:569-578, 1994. PUBMED Abstract
  4. Arner B: A comparative clinical trial of different subcutaneous doses of terbutaline and orciprenaline in bronchial asthma. Acta Med Scand Suppl 512:45-48, 1970. PUBMED Abstract
  5. Aylward M, Maddock J, Davies DE, et al: Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects. Eur J Respir Dis 65:283-291, 1984. PUBMED Abstract
  6. Barnes PJ: Corticosteroids: the drugs to beat. Eur J Pharmacol 533:2-14, 2006. PUBMED Abstract
  7. Barnes PJ: Current therapy for asthma. In Hansel TT, Barnes PJ, editors: New drugs for asthma, allergy and COPD, vol 31, Basel, 2001, Karger.
  8. Barnes PJ: How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 148:245-254, 2006. PUBMED Abstract
  9. Barnes PJ: Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2:334-339, 2005. PUBMED Abstract
  10. Barnes PJ: Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 167:813-818, 2003. PUBMED Abstract
  11. Bateman ED, Boushey HA, Bousquet J, et al: Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 170:836-844, 2004. PUBMED Abstract
  12. Bhatnagar P, Guleria R, Kukreti R: Pharmacogenomics of β2-agonist: key focus on signaling pathways. Pharmacogenomics 7:919-933, 2006. PUBMED Abstract
  13. Blake K: Review of guidelines and the literature in the treatment of acute bronchospasm in asthma. Pharmacotherapy 26:148S-155S, 2006. PUBMED Abstract
  14. Bousquet J, Jeffery PK, Busse WW, et al: Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 161:1720-1745, 2000. PUBMED Abstract
  15. Broadley KJ: β-Adrenoceptor responses of the airways: for better or worse? Eur J Pharmacol 533:15-27, 2006. PUBMED Abstract
  16. Chesnutt M, Kazarys S: Asthma therapy in the nineties: focus on inflammation. Hosp Form 27:166-187, 1992.
  17. Church M, Polosa R, Rimmer S: Cromolyn sodium and nedocromil sodium: mast cell stabilizers, neuromodulators, or anti-inflammatory drugs? In Kaliner MA, Barnes PJ, Persson CGA, editors: Asthma: its pathology and treatment. Lung biology in health and disease, vol 49, New York, 1991, Marcel Dekker.
  18. Currie GP, Lee DK, Lipworth BJ: Long-acting β2-agonists in asthma: not so SMART? Drug Saf 29:647-656, 2006. PUBMED Abstract
  19. Currie GP, McLaughlin K: The expanding role of leukotriene receptor antagonists in chronic asthma. Ann Allergy Asthma Immunol 97:731-741, 2006. PUBMED Abstract
  20. D’Alonzo GE, Nathan RA, Henochowicz S, et al: Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 271:1412-1416, 1994. PUBMED Abstract
  21. D’Amato G: Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur J Pharmacol 533:302-307, 2006. PUBMED Abstract
  22. Dahlen SE: Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 533:40-56, 2006. PUBMED Abstract
  23. Derendorf H: Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 91(Suppl A):22-28, 1997. PUBMED Abstract
  24. Derendorf H, Nave R, Drollmann A, et al: Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 28:1042-1050, 2006. PUBMED Abstract
  25. Disse B, Speck GA, Rominger KL, et al: Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64:457-464, 1999. PUBMED Abstract
  26. Donohue JF: Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2:272-281, 2005. PUBMED Abstract
  27. Eder W, Ege MJ, von Mutius E: The asthma epidemic. N Engl J Med 355:2226-2235, 2006. PUBMED Abstract
  28. Ernst P, McIvor A, Ducharme FM, et al: Safety and effectiveness of long-acting inhaled β-agonist bronchodilators when taken with inhaled corticosteroid. Ann Intern Med 145:692-694, 2006. PUBMED Abstract
  29. Faurschou P, Steffensen I, Jacques L: Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group. Eur Respir J 9:1885-1890, 1996. PUBMED Abstract
  30. Foe K, Brown KF, Seale JP: Comparative kinetics of metabolism of beclomethasone propionate esters in human lung homogenates and plasma. J Pharm Sci 89:1143-1150, 2000. PUBMED Abstract
  31. Giembycz MA, Newton R: Beyond the dogma: novel β2-adrenoceptor signalling in the airways. Eur Respir J 27:1286-1306, 2006. PUBMED Abstract
  32. Global Initiative for Asthma expert panel: Global strategy for asthma management and prevention, Medical Communications Resources, 2009 update. Available at http://www.ginasthma.org. Accessed January 16, 2010.
  33. Grant SM, Goa KL, Fitton A, et al: Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 40:412-448, 1990. PUBMED Abstract
  34. Green SA, Spasoff AP, Coleman RA, et al: Sustained activation of a G protein-coupled receptor via “anchored” agonist binding: molecular localization of the salmeterol exosite within the β2-adrenergic receptor. J Biol Chem 271:24029-24035, 1996. PUBMED Abstract
  35. Gross NJ: Anticholinergic agents in asthma and COPD. Eur J Pharmacol 533:36-39, 2006. PUBMED Abstract
  36. Hanania NA, Chapman KR, Kesten S: Adverse effects of inhaled corticosteroids. Am J Med 98:196-208, 1995. PUBMED Abstract
  37. Hupp W: Dental management of patients with obstructive pulmonary diseases. In Hupp J, editor: Medical conditions and their impact on dental care, New York, 2006, Elsevier. PUBMED Abstract
  38. Ito K, Lim S, Caramori G, et al: A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 99:8921-8926, 2002. PUBMED Abstract
  39. Kelly HW: Risk versus benefit considerations for the β2-agonists. Pharmacotherapy 26:164S-174S, 2006. PUBMED Abstract
  40. Louie S, Yoneda KY, Kenyon NJ: Treatment of asthma in adults. In Gershwin ME, Albertson TE, editors: Bronchial asthma: principles of diagnosis and treatment, ed 4, Totowa, NJ, 2001, Humana.
  41. MacNee W: Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:258-266, 2005. PUBMED Abstract
  42. Man SF, Sin DD: Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit? Drugs 65:579-591, 2005. PUBMED Abstract
  43. Marin MG: Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Chest 112:29-33, 1997. PUBMED Abstract
  44. McGraw DW, Almoosa KF, Paul RJ, et al: Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox. J Clin Invest 112:619-626, 2003. PUBMED Abstract
  45. Murray CJ, Lopez AD: Evidence-based health policy—lessons from the Global Burden of Disease Study. Science 274:740-743, 1996. PUBMED Abstract
  46. Naedele-Risha R, Dorinsky P, Craig TJ: Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting β-agonists with inhaled corticosteroids. J Am Osteopath Assoc 101:526-533, 2001.PUBMED Abstract
  47. Nowak D: Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med 100:1907-1917, 2006. PUBMED Abstract
  48. Ogawa Y, Calhoun WJ: The role of leukotrienes in airway inflammation. J Allergy Clin Immunol 118:789-798; quiz 799-800, 2006. PUBMED Abstract
  49. Pearlman DS, Chervinsky P, LaForce C, et al: A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 327:1420-1425, 1992. PUBMED Abstract
  50. Rahman I, Adcock IM: Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 28:219-242, 2006. PUBMED Abstract
  51. Reilly K, Salluzzo R: Theophylline toxicity. Resid Staff Physician 37:55-57, 1991.
  52. Robinson RE, Cummings WR, Deffenbaugh EB: Effectiveness of guaifenesin as an expectorant: a cooperative double blind study. Curr Ther Res 22:284-296, 1977.
  53. Roth M, Johnson PRA, Rüdiger JJ, et al: Interaction between glucocorticoids and β2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360:1293-1299, 2002.
  54. Sin DD, Man SF: Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur J Pharmacol 533:28-35, 2006. PUBMED Abstract
  55. Sin DD, Man SF: Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. Proc Am Thorac Soc 3:624-629, 2006. PUBMED Abstract
  56. Stevenson DD, Szczeklik A: Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118:773-786, 2006. PUBMED Abstract
  57. Szczeklik A, Sanak M: The broken balance in aspirin hypersensitivity. Eur J Pharmacol 533:145-155, 2006. PUBMED Abstract
  58. Thompson N: Non-steroidal prophylactic agents: mode of action and place in management. In Clark TJ, Godfrey S, Lee T, editors: Asthma, London, 2000, Arnold.
  59. van Schayck CP, Reid J: Effective management of COPD in primary care—the role of long-acting beta agonist/inhaled corticosteroid combination therapy. Prim Care Respir J 15:143-151, 2006. PUBMED Abstract
  60. Wenzel SE: New approaches to anti-inflammatory therapy for asthma. Am J Med 104:287-300, 1998. PUBMED Abstract
  61. Woolcock A, Lundback B, Ringdal N, et al: Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153:1481-1488, 1996. PUBMED Abstract

GENERAL REFERENCES

  1. Adcock IM, Caramori G, Chung KF: New targets for drug development in asthma, Lancet 372:1073-1087, 2008. PUBMED Abstract
  2. Mahmoudi M, editor: Allergy and asthma: practical diagnosis and management, New York, 2008, McGraw Hill Medical.